2015
DOI: 10.1016/j.jaci.2014.06.022
|View full text |Cite
|
Sign up to set email alerts
|

Classification of common variable immunodeficiencies using flow cytometry and a memory B-cell functionality assay

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
20
0
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(21 citation statements)
references
References 49 publications
0
20
0
1
Order By: Relevance
“…[24][25][26][27]44,45 However, the plethora of immunological abnormalities and their unequal distribution among different cohorts have made it challenging to uniformly identify subgroups in the CVID population.…”
Section: A B C Dmentioning
confidence: 99%
“…[24][25][26][27]44,45 However, the plethora of immunological abnormalities and their unequal distribution among different cohorts have made it challenging to uniformly identify subgroups in the CVID population.…”
Section: A B C Dmentioning
confidence: 99%
“…cluding susceptibility to sinopulmonary infections, granulomatous disease, lymphoproliferation, and autoimmunity (in subsets of patients) (88)(89)(90). Attempts have been made over the past decade or longer to classify CVID patients based on differences in peripheral B cell subsets, and some of these have provided clinical correlations, which may have prognostic value in subgroups of patients (91)(92)(93)(94)(95)(96)(97)(98). B cell subset analysis, in particular evaluation of memory B cells and switched memory B cells, has been incorporated into the newer diagnostic criteria as an accessory criterion (88), as the majority of CVID patients have impaired peripheral B cell differentiation and reduced class-switched memory B cells.…”
Section: Cellular Immunophenotyping In Pidsmentioning
confidence: 99%
“…Rösel et al 46 examined the memory B cell ELISPOT assay in fifteen CVID patients as another tool to characterize antibody response and B cell function and concluded that this test might be useful to help identify patients who might benefit from treatment with B cell stimulating cytokines. Mousalleum and collaborators 47 reported their experience of using whole genome sequencing (WES) to diagnose molecular defects in six patients with unidentified PIDs.…”
Section: Diagnostic Testing Of Primary Immunodeficienciesmentioning
confidence: 99%